Effect of sodium-glucose cotransporter 2 inhibitor on proximal tubular function and injury in patients with type 2 diabetes: A randomized controlled trial

Clinical Kidney Journal

Volumn 12, Issue 3, 2019, Pages 326-332

  Satirapoj, Bancha ^a   Korkiatpitak, Pattharamon ^a   Supasyndh, Ouppatham ^a  

^a PHRAMONGKUTKLAO HOSPITAL   (Thailand)

Author keywords

Cystatin C; Dapagliflozin; Kidney injury molecule 1; Sodium glucose cotransporter 2 inhibitor; Type 2 diabetes

Indexed keywords

ALBUMIN; CREATININE; CYSTATIN C; DAPAGLIFLOZIN; HEMOGLOBIN A1C; KIDNEY INJURY MOLECULE 1; PHOSPHATE; PLACEBO; URIC ACID;

ADULT; ADVERSE OUTCOME; ALBUMIN BLOOD LEVEL; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; CREATININE URINE LEVEL; DIABETIC PATIENT; DRUG EFFECT; EXCRETION FRACTION; FEMALE; GLOMERULUS FILTRATION RATE; HEMOGLOBIN BLOOD LEVEL; HUMAN; KIDNEY INJURY; KIDNEY PROXIMAL TUBULE; KIDNEY TUBULE FUNCTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RENAL PROTECTION; URINE SAMPLING;

EID: 85071190343     PISSN: 20488505     EISSN: 20488513     Source Type: Journal    
DOI: 10.1093/ckj/sfy122     Document Type: Article

References (29)

1. Goff DC Jr, Gerstein HC, Ginsberg HN et al. Prevention of cardiovascular disease in persons with type 2 diabetes mellitus: current knowledge and rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol 2007; 99: 4i-20i
2. Ingsathit A. Thakkinstian, A Chaiprasert, P et al. Prevalence and risk factors of chronic kidney disease in the Thai adult population: Thai SEEK study. Nephrol Dial Transplant 2010; 25: 1567-1575
3. Satirapoj B, Supasyndh O, Mayteedol N et al. Metabolic syndrome and its relation to chronic kidney disease in a Southeast Asian population. Southeast Asian J Trop Med Public Health 2011; 42: 176-183
4. Satirapoj B, Adler SG. Comprehensive approach to diabetic nephropathy. Kidney Res Clin Pract 2014; 33: 121-131
5. Satirapoj B. Review on pathophysiology and treatment of diabetic kidney disease. J Med Assoc Thai 2010; 93(Suppl 6): S228-S241
6. Kasichayanula S, Liu X, Lacreta F et al. Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2. Clin Pharmacokinet 2014; 53: 17-27
7. Bailey CJ, Gross JL, Pieters A et al. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet 2010; 375: 2223-2233
8. Perkins BA, Cherney DZI, Partridge H et al. Sodium-glucose cotransporter 2 inhibition and glycemic control in type 1 diabetes: results of an 8-week open-label proof-of-concept trial. Diabetes Care 2014; 37: 1480-1483
9. Zinman B, Wanner C, Lachin JM et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015; 373: 2117-2128
10. Satirapoj B. Sodium-glucose cotransporter 2 inhibitors with renoprotective effects. Kidney Dis 2017; 3: 24-32
11. Gangadharan Komala M, Gross S, Mudaliar H et al. Inhibition of kidney proximal tubular glucose reabsorption does not prevent against diabetic nephropathy in type 1 diabetic eNOS knockout mice. PLoS One 2014; 9: e108994
12. Panchapakesan U, Pegg K, Gross S et al. Effects of SGLT2 inhibition in human kidney proximal tubular cells-renoprotection in diabetic nephropathy? PLoS One 2013; 8: e54442
13. Vallon V, Rose M, Gerasimova M et al. Knockout of Na-glucose transporter SGLT2 attenuates hyperglycemia and glomerular hyperfiltration but not kidney growth or injury in diabetes mellitus. Am J Physiol Renal Physiol 2013; 304: F156-F167
14. Vallon V, Gerasimova M, Rose MA et al. SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice. Am J Physiol Renal Physiol 2014; 306: F194-F204
15. Wanner C, Inzucchi SE, Lachin JM et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 2016; 375: 323-334
16. Heerspink HJ, Johnsson E, Gause-Nilsson I et al. Dapagliflozin reduces albuminuria in patients with diabetes and hypertension receiving renin-angiotensin blockers. Diabetes Obes Metab 2016; 18: 590-597
17. Cherney D, Lund SS, Perkins BA et al. The effect of sodium glucose cotransporter 2 inhibition with empagliflozin on microalbuminuria and macroalbuminuria in patients with type 2 diabetes. Diabetologia 2016; 59: 1860-1870.
18. Heerspink HJ, Desai M, Jardine M et al. Canagliflozin slows progression of renal function decline independently of glycemic effects. J Am Soc Nephrol 2017; 28: 368-375
19. Viberti GC, Hill RD, Jarrett RJ et al. Microalbuminuria as a predictor of clinical nephropathy in insulin-dependent diabetes mellitus. Lancet 1982; 1: 1430-1432
20. Satirapoj B. Tubulointerstitial biomarkers for diabetic nephropathy. J Diabetes Res 2018; 2018: 2852398
21. Satirapoj B, Aramsaowapak K, Tangwonglert T et al. Novel tubular biomarkers predict renal progression in type 2 diabetes mellitus: a prospective cohort study. J Diabetes Res 2016; 2016: 3102962
22. Tervaert TWC, Mooyaart AL, Amann K et al. Pathologic classification of diabetic nephropathy. J Am Soc Nephrol 2010; 21: 556-563
23. Maltese G, Abou-Saleh A, Gnudi L et al. Preventing diabetic renal disease: the potential reno-protective effects of SGLT2 inhibitors. Br J Diabetes 2015; 15: 114-118.
24. Maeda S, Matsui T, Takeuchi M et al. Sodium-glucose cotransporter 2-mediated oxidative stress augments advanced glycation end products-induced tubular cell apoptosis. Diabetes Metab Res Rev 2013; 29: 406-412
25. Dekkers CCJ, Petrykiv S, Laverman GD et al. Effects of the SGLT-2 inhibitor dapagliflozin on glomerular and tubular injury markers. Diabetes Obes Metab 2018; 20: 1988-1993
26. Chino Y, Samukawa Y, Sakai S et al. SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria. Biopharm Drug Dispos 2014; 35: 391-404
27. List JF, Woo V, Morales E et al. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care 2009; 32: 650-657
28. Doblado M, Moley KH. Facilitative glucose transporter 9, a unique hexose and urate transporter. Am J Physiol Endocrinol Metabol 2009; 297: E831-E835
29. Cook DG, Shaper AG, Thelle DS et al. Serum uric acid, serum glucose and diabetes: relationships in a population study. Postgrad Med J 1986; 62: 1001-1006